Contact: Steve McKinley, MS, PhD, Director Sales & Marketing
R&D LifeSciences, LLC.
Phone: 877-874-0125 Email: stevem@rdlifesciences.com
May 2010, Menomonie, WI – R&D LifeSciences, LLC, an innovative biotech solutions company has signed a technology and marketing agreement with Aova Technologies, an agricultural biotech company headquartered in Madison, WI, to market their patented, naturally produced micro feed ingredient aPLA2 Technology.
According to David Zehendner, President/CEO of R&D LifeSciences (R&DL), “This technology/marketing agreement allows R&DL to introduce an entirely new class of feed ingredient technology via their global distribution channels.” Aova’s egg antibody platform utilizes patented technologies to produce innovative feed additives containing enzyme-specific antibodies (aPhospholipase A2) designed to mitigate gut inflammation to aid animal growth, efficiency and development.
According to Jesus Martinez, CEO of Aova Technologies, “This technology sharing and marketing agreement allows R&DL and Aova Technologies the opportunity to position this new technology across a global feeding distribution platform not available to Aova in the past. It also allows Aova to continue our research to help enhance this technology and support R&DL’s sales and technical support for years to come. We’re excited to be linked to such an aggressive, professional organization that is committed to bringing natural feed ingredients to the global feed ingredients marketplace.”
R&DL will use the technology to introduce new ReNuvigen™ for the reduction of gut inflammation. “By incorporating ReNuvigen™ (PLA2) in our current feed ingredients, producers can improve animal performance and enhance their bottom line,” adds Zehendner. “The antibody titer has also increased, allowing the recommended inclusion level to be lowered, significantly decreasing the cost for producers.”
“In multiple species, controlled studies, animals exhibited improved health as demonstrated by reduced mortality and decreased medication cost or medicated feed cost,” adds Dave Cook, Ph.D., Technical Services Director for R&DL. “Research trials have shown improved animal health with greater feed efficiency, average daily gain and uniformity with ReNuvigen™. ReNuvigen™ has shown to improve feed conversion by 3% to 4% and average daily gain (ADG) by 5.5%. We plan to incorporate it with our innovative probiotics, enzymatic, anti-bacterial and specific egg globulin feed ingredients to bring even more production and feed cost savings to producers.”
For more information on new ReNuvigen™ or R&D LifeSciences, visit http://www.RDLifeSciences.com or call 877-874-0125 or 715-231-2150.
About R&D LifeSciences, LLC
R&D LifeSciences, LLC, is an innovative biotech solutions company specialized in the manufacturing, marketing and global distribution of natural feeding ingredients. R&D LifeSciences brands include – Zymace™, Lactomace™, Protemace™, Flomace™, Phytomace™, Bactomace™and ReNuvigen™. For more information on R&D LifeSciences, visit http://www.RDLifeSciences.com or call 877-874-0125 or 715-231-2150.
About Aova Technologies
Aova Technologies, Inc. is a biotechnology company organized in 2001 for the purpose of commercializing the company’s proprietary technologies and products to offer the producer and feed nutritionist a new strategy in animal nutrition. The company has developed scalable production and manufacturing processes that allowed for U.S. market entry in 2005. Aova Tech is a privately held company with offices in Madison, WI. For more information please visit the company’s website at http://www.aovatech.com.
